• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Brochures
  • Events
  • Related Websites

Research Article Abstract: Buprenorphine Compared with Methadone to Treat Pregnant Women with Opioid Use Disorder: A Systematic Review and Meta-Analysis of Safety in The Mother, Fetus and Child

June 22, 2016 by ATForum

Aims

To assess the safety of buprenorphine compared with methadone to treat pregnant women with opioid use disorder.

Methods

We searched PubMed, Embase and the Cochrane Library from inception through February 2015 for randomized controlled trials (RCT) and observational cohort studies (OBS) that compared buprenorphine with methadone for treating opioid-dependent pregnant women. Two reviewers independently assessed titles and abstracts of all search results and full texts of potentially eligible studies reporting original data for maternal/fetal/infant death, preterm birth, fetal growth outcomes, fetal/congenital anomalies, fetal/child neurodevelopment, and/or maternal adverse events. We ascertained each study’s risk of bias using validated instruments and assessed the strength of evidence for each outcome using established methods. We computed effect sizes using random-effects models for each outcome with 2 or more studies.

Results

Three RCTs (N = 223) and 15 cohort OBS (N = 1923) met inclusion criteria. In meta-analyses using unadjusted data and methadone as comparator, buprenorphine was associated with lower risk of preterm birth [RCT risk ratio (RR) 0.40 (95% CI 0.18, 0.91); OBS RR 0.67 (95% CI 0.50, 0.90)], greater birth weight [RCT weighted mean difference (WMD) 277 g (95% CI 104, 450); OBS WMD 265 g (95% CI 196, 335)] and larger head circumference [RCT WMD 0.90 cm (95% CI 0.14, 1.66); OBS WMD 0.68 cm (95% CI 0.41, 0.94)]. No treatment differences were observed for spontaneous fetal death, fetal/congenital anomalies and other fetal growth measures, although the power to detect such differences may be inadequate due to small sample sizes.

Conclusions

Moderately strong evidence indicates lower risk of preterm birth, greater birth weight and larger head circumference with buprenorphine treatment of maternal opioid use disorder during pregnancy compared with methadone treatment, and no greater harms.

http://onlinelibrary.wiley.com/doi/10.1111/add.13462/abstract

Source: Addiction Journal – Accepted manuscript online May 25, 2016

Filed Under: News Updates

Primary Sidebar

Upcoming Events

AATOD
April 10-14, 2021
Las Vegas, NV
https://www.eventscribe.com/2021/AATOD/

The Americam Society of Addiction Medicine (ASAM) 51th Annual Medical-Scientific Conference
Thursday, April 22, 2021 to Saturday, April 24, 2021
Virtual
https://www.drugabuse.gov/news-events/meetings-events/2021/04/americam-society-addiction-medicine-asam-51th-annual-medical-scientific-conference

APA 2021 Annual Meeting
Saturday, May 1, 2021 to Wednesday, May 5, 2021
Los Angeles, California
https://www.drugabuse.gov/news-events/meetings-events/2021/05/apa-2021-annual-meeting

View More Upcoming Events…

ATForum.com

  • Newsletter
  • News Updates
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

This educational resource is supported by Hikma Pharmaceuticals USA Inc.

Sign up for News!

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Clinco Communications, Inc., 1808 N. Arlington Heights Road, Arlington Heights, IL, 60004, http://www.atforum.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

© 2021 Addiction Treatment Forum · All Rights Reserved